Alfred Johnson, MD
Internal Medicine · Jefferson City, MONPI 1396900510
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations.
Across 173 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$651
- Pfizer$523
- GSK$293
- Amgen$158
- Novo Nordisk$148
- Dexcom, Inc.$142
- plus $921 from 27 others
Across 9 payments — averaging $6751.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$39K
- Sanofi Pasteur Inc.$22K
What the payments were for
- Food & beverage$2,836100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $651 |
| Pfizer | 39 | $523 |
| GSK | 19 | $293 |
| Amgen | 10 | $158 |
| Novo Nordisk | 9 | $148 |
| Dexcom, Inc. | 6 | $142 |
| Lilly USA, LLC | 8 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $106 |
| Edwards Lifesciences | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Lundbeck LLC | 2 | $50 |
| Boehringer Ingelheim | 3 | $44 |
| AstraZeneca | 3 | $43 |
| Supernus Pharmaceuticals, Inc. | 3 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Sobi, Inc | 2 | $34 |
| Novartis | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Beigene USA, Inc. | 1 | $24 |
| Vertex | 1 | $20 |
| Merck | 1 | $20 |
| Abbott | 1 | $19 |
| Verrica Pharmaceuticals Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Seqirus USA Inc | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,836 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $119,800 |
| EliquisApixaban | 63 | $65,891 |
| TrulicityDulaglutide | 28 | $39,000 |
| MounjaroTirzepatide | 24 | $31,457 |
| XareltoRivaroxaban | 26 | $26,061 |
| JardianceEmpagliflozin | 24 | $19,981 |
| RybelsusSemaglutide | 14 | $12,823 |
| FarxigaDapagliflozin Propanediol | 12 | $10,338 |
| JanuviaSitagliptin Phosphate | 11 | $8,831 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $8,199 |
| LinzessLinaclotide | 14 | $7,754 |
| VascepaIcosapent Ethyl | 20 | $7,029 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 50 | $4,181 |
| Atorvastatin Calcium | 369 | $3,797 |
| Omeprazole | 256 | $3,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $148 | $132,623123 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $119 | $70,45752 claims |
| PfizerEliquis | $523 | $65,89163 claims |
| Johnson & JohnsonXarelto | $14 | $26,06126 claims |
| Boehringer IngelheimJardiance | $44 | $19,98124 claims |
| AstraZenecaFarxiga, Symbicort | $43 | $13,60726 claims |
| AbbVieLinzess, Synthroid | $651 | $8,96559 claims |
| MerckJanuvia | $20 | $8,83111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Jefferson City
- Timothy SmithSaint Peters$428K
- Craig DietzKansas City$226K
- Kevin SuttmoellerKansas City$198K
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Dima DandachiColumbia$157K
- Justin SteinkampSaint Charles$139K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.